| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
argenx SE (NASDAQ: ARGX)
ARGX Technical Analysis
5
| As on 9th Jun 2023 ARGX STOCK Price closed @ 390.62 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 335.70 & Strong Buy for SHORT-TERM with Stoploss of 297.26 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ARGXSTOCK Price
| Open | 391.30 | Change | Price | % |
| High | 393.31 | 1 Day | -0.66 | -0.17 |
| Low | 389.34 | 1 Week | 1.92 | 0.49 |
| Close | 390.62 | 1 Month | 9.74 | 2.56 |
| Volume | 111848 | 1 Year | 39.04 | 11.10 |
| 52 Week High 422.58 | 52 Week Low 254.45 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ARGX Daily Charts |
ARGX Intraday Charts |
Whats New @ Bazaartrend |
ARGX Free Analysis |
|
|
ARGX Important Levels Intraday
| RESISTANCE | 398.27 |
| RESISTANCE | 395.82 |
| RESISTANCE | 394.30 |
| RESISTANCE | 392.78 |
| SUPPORT | 388.46 |
| SUPPORT | 386.94 |
| SUPPORT | 385.42 |
| SUPPORT | 382.97 |
ARGX Forecast May 2024
| 4th UP Forecast | 543.26 |
| 3rd UP Forecast | 494.31 |
| 2nd UP Forecast | 464.05 |
| 1st UP Forecast | 433.79 |
| 1st DOWN Forecast | 347.45 |
| 2nd DOWN Forecast | 317.19 |
| 3rd DOWN Forecast | 286.93 |
| 4th DOWN Forecast | 237.98 |
ARGX Weekly Forecast
| 4th UP Forecast | 417.71 |
| 3rd UP Forecast | 409.02 |
| 2nd UP Forecast | 403.65 |
| 1st UP Forecast | 398.28 |
| 1st DOWN Forecast | 382.96 |
| 2nd DOWN Forecast | 377.59 |
| 3rd DOWN Forecast | 372.22 |
| 4th DOWN Forecast | 363.53 |
ARGX Forecast2024
| 4th UP Forecast | 726.86 |
| 3rd UP Forecast | 619.03 |
| 2nd UP Forecast | 552.37 |
| 1st UP Forecast | 485.72 |
| 1st DOWN Forecast | 295.52 |
| 2nd DOWN Forecast | 228.87 |
| 3rd DOWN Forecast | 162.21 |
| 4th DOWN Forecast | 54.38 |
argenx SE ( NASDAQ USA Symbol : ARGX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ARGX Business Profile
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Address: Willemstraat 5, Breda, Netherlands, 4811 AH
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service